Trump clashes with doctors on virus treatment The U.S. government’s National Institutes of Health launched an official clinical trial of the anti-malaria drug that President Trump has already touted as a possible “game changer” in the fight against the new coronavirus. The NIH’s National Heart, Lung, and Blood Institute (NHLBI) announced Thursday that the first patients had been enrolled at Vanderbilt University Medical Center in Nashville in the trial of hydroxychloroquine to assess its safety and efficacy in treating COVID-19 patients. The statement did not say how many patients there had been given the drug already, but noted the goal was to “enroll more than 500 adults who are currently hospitalized with COVID-19 or in an emergency department with anticipated hospitalization,” across “dozens” of centers that form a drug trials network across the U.S. called the PETAL Network. “All participants in the study will continue to receive clinical care as indicated for their condition. Those randomized to the experimental intervention will also receive hydroxychloroquine,” the statement said. The science behind treating coronavirus “Many U.S. hospitals are currently using hydroxychloroquine as first-line therapy for hospitalized patients with COVID-19 despite extremely limited clinical data supporting its effectiveness,” said lead researcher for the

Continue To Full Article